Skip to content

Observation on clinical efficacy of "Yinchen Qingzhi Drink" on non-alcoholic fatty liver disease (damp heat internal accumulation combined with qi stagnation and blood stasis type)

Observation on clinical efficacy of "Yinchen Qingzhi Drink" on non-alcoholic fatty liver disease (damp heat internal accumulation combined with qi stagnation and blood stasis type)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001765
Enrollment
Unknown
Registered
2025-09-16
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

Treatment group:Yinchen Qingzhen Drink 1 dose/time, twice a day, decocted in water, taken for 8 weeks
Control group:Silybin Megluamine Tablets 100mg/time, three times a day, orally after meals, for a total of 8 weeks

Sponsors

Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria for non-alcoholic fatty liver disease in Western medicine and those who have damp heat inclusion combined with qi stagnation and blood stasis syndrome in traditional Chinese medicine; (2) Those who are aged 18 to 70 years old; (3) Those who have stopped using other drugs that may interfere with the test results for more than 1 month; (4) They are fully aware of this topic and participate voluntarily, and can cooperate in filling out investigation materials and signing an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those who do not meet the diagnostic criteria for non-alcoholic fatty liver disease in Western medicine and (or) Chinese medicine diagnosis criteria for internal damp heat accumulation and qi stagnation and blood stasis syndrome; (2) Those who are less than 18 years old or older than 70 years old; (3) Those who are combined with tumors, blood diseases and other major diseases; (4) Patients with mental illness; (5) Those who do not (or are difficult to) cooperate with the trial arrangement during the treatment process and use other drugs on their own, which may affect the judgment of clinical efficacy; (6) Patients who are unwilling to sign an informed consent form.

Design outcomes

Primary

MeasureTime frame
Liver function;Blood lipid;

Secondary

MeasureTime frame
Abdominal color ultrasound;

Countries

China

Contacts

Public ContactMeihui Xia

Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

1239658194@qq.com18724625832

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026